A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Harvey RD, Owonikoko TK, Lewis CM, Akintayo A, Chen Z, Tighiouart M, Ramalingam SS, Fanucchi MP, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS.
Harvey RD, et al.
Br J Cancer. 2013 Mar 5;108(4):762-5. doi: 10.1038/bjc.2012.604. Epub 2013 Jan 15.
Br J Cancer. 2013.
PMID: 23322195
Free PMC article.
Clinical Trial.